Abstract: The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.
Type:
Application
Filed:
June 16, 2022
Publication date:
December 8, 2022
Applicant:
ASPIAIR GMBH
Inventors:
Karlheinz NOCKER, Sebastian CANISIUS, Gerhard SCHEUCH
Abstract: The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
July 5, 2022
Assignee:
ASPIAIR GMBH
Inventors:
Karlheinz Nocker, Sebastian Canisius, Gerhard Scheuch